Filing Summary
Business Context and Reporting Period
This Form 6-K was filed by NLS Pharmaceutics Ltd., a Swiss foreign private issuer, on February 8, 2021, for the month of February 2021 (Report No. 2). The filing reports amendments to the company’s Articles of Association. The request metadata identifies the company as Newcelx Ltd.; however, the filing names NLS Pharmaceutics Ltd.
Material Corporate and Capital Changes
- Amended and Restated Articles of Association were filed with the Commercial Registry of the Canton of Nidwalden on February 2, 2021 and became effective February 5, 2021.
- Issued share capital increased to CHF 235,826.50, consisting of 11,791,325 common shares.
- Authorized share capital increased to CHF 117,551.80, consisting of 5,877,590 common shares.
- The authorized share capital permits the board of directors to increase share capital within two years without further shareholder approval.
Financial Metrics, Liquidity, and Debt
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, operating results, or other financial performance metrics.
Guidance, Outlook, Risks, and Unusual Items
The filing does not provide management guidance, business outlook, risk updates, contingencies, or unusual operating items. The principal reported development is the increase in issued and authorized share capital, which may facilitate future equity issuance and potential dilution.
Key Facts to Verify
- Confirm the identity of the registrant, because the supplied metadata references Newcelx Ltd. while the filing identifies NLS Pharmaceutics Ltd.
- Review Exhibits 3.1 and 3.2 for the complete amended Articles of Association.
- Assess the potential dilution and use of the additional authorized share capital.
- Verify the stated share counts and CHF amounts against the company’s subsequent corporate and securities filings.